Year-end Sale % OFF 
Abstract
Objective: The study was aimed to evaluate the effect of Ranolazine on Fasting Plasma Glucose (FPG) in patients of Type II Diabetes Mellitus with Stable Angina as add on therapy. Material and Methods: An open-labeled, randomized, controlled parallel group study was conducted in 76 diagnosed patients of Type II Diabetes Mellitus with Stable Angina at S.N. medical College and Hospital, Agra. The selected patients randomly assigned into 2 groups, Control group (Group 1): was on their regular therapy during the 8-week study period. Test group (Group 2): was on Ranolazine 500mg BD (orally) in addition to their regular therapy during the 8week study period. The FPG measurement was done at baseline, repeated after 4weeks and at the end of treatment (i.e at 8week). All data obtained were expressed as mean
Highlights
Prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide
On the basis of data from the Centers for Disease Control Diabetes Surveillance System, it has been estimated that ≈30% of individuals with DM 35 to years of age have cardiovascular disease (CVD) and that this proportion is as high as 45% among DM patients to 74 years of age.[3]
We have analyzed the effect of Ranolazine on Fasting Plasma Glucose (FPG) in patients of Type –II Diabetes Mellitus with Stable Angina as add on therapy with their ongoing regular therapy
Summary
Prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. Nowadays over 360 million people are suffering from diabetes and it is expected that its prevalence reach a staggering 552 million by 2030 .1 Diabetes mellitus(DM) substantial associated with cardiovascular morbidity and mortality.[2]. Several clinical trials have shown that patients with CAD treated with β-blockers and calcium channel blockers have consistently and significantly higher rates of newly diagnosed diabetes because of the prodiabetic effects of these medications.[7]. Ranolazine, a novel oral antianginal agent, It improves exercise performance and reduces the frequency of angina in patients with stable angina.[8,9] In addition to its antianginal effects, Ranolazine has been shown to reduce HbA1c in patients with CAD and diabetes in two clinical studies.[10,11] Studies of Ranolazine effect on FPG are lacking. The objective of the present study is to evaluate the effect of Ranolazine on FPG in patients of Type –II Diabetes Mellitus with Stable Angina as add on therapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Biomedical and Advance Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
